萊斯康製藥第二季收入大減 淨虧損3178萬美元 現金儲備增至1.9億美元

lxrx-20260630Q2FALSE2026--12-310001062822onexbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:pureutr:Ratelxrx:segment00010628222026-01-012026-06-3000010628222026-08-0300010628222026-06-3000010628222025-12-310001062822us-gaap:ProductMember2026-04-012026-06-300001062822us-gaap:ProductMember2025-04-012025-06-300001062822us-gaap:ProductMember2026-01-012026-06-300001062822us-gaap:ProductMember2025-01-012025-06-300001062822us-gaap:LicenseMember2026-04-012026-06-300001062822us-gaap:LicenseMember2025-04-012025-06-300001062822us-gaap:LicenseMember2026-01-012026-06-300001062822us-gaap:LicenseMember2025-01-012025-06-3000010628222026-04-012026-06-3000010628222025-04-012025-06-3000010628222025-01-012025-06-300001062822naics:ZZ5417142026-04-012026-06-300001062822naics:ZZ5417142025-04-012025-06-300001062822naics:ZZ5417142026-01-012026-06-300001062822naics:ZZ5417142025-01-012025-06-300001062822lxrx:SellingGeneralAndAdministrativeExpenseMember2026-04-012026-06-300001062822lxrx:SellingGeneralAndAdministrativeExpenseMember2025-04-012025-06-300001062822lxrx:SellingGeneralAndAdministrativeExpenseMember2026-01-012026-06-300001062822lxrx:SellingGeneralAndAdministrativeExpenseMember2025-01-012025-06-300001062822us-gaap:CommonStockMember2024-12-310001062822us-gaap:PreferredStockMember2024-12-310001062822us-gaap:AdditionalPaidInCapitalMember2024-12-310001062822us-gaap:RetainedEarningsMember2024-12-310001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001062822us-gaap:TreasuryStockCommonMember2024-12-3100010628222024-12-310001062822us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-3100010628222025-01-012025-03-310001062822us-gaap:CommonStockMember2025-01-012025-03-310001062822us-gaap:TreasuryStockCommonMember2025-01-012025-03-310001062822us-gaap:RetainedEarningsMember2025-01-012025-03-310001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001062822us-gaap:CommonStockMember2025-03-310001062822us-gaap:PreferredStockMember2025-03-310001062822us-gaap:AdditionalPaidInCapitalMember2025-03-310001062822us-gaap:RetainedEarningsMember2025-03-310001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001062822us-gaap:TreasuryStockCommonMember2025-03-3100010628222025-03-310001062822us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-300001062822us-gaap:CommonStockMember2025-04-012025-06-300001062822us-gaap:RetainedEarningsMember2025-04-012025-06-300001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-300001062822us-gaap:CommonStockMember2025-06-300001062822us-gaap:PreferredStockMember2025-06-300001062822us-gaap:AdditionalPaidInCapitalMember2025-06-300001062822us-gaap:RetainedEarningsMember2025-06-300001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300001062822us-gaap:TreasuryStockCommonMember2025-06-3000010628222025-06-300001062822us-gaap:CommonStockMember2025-12-310001062822us-gaap:PreferredStockMember2025-12-310001062822us-gaap:AdditionalPaidInCapitalMember2025-12-310001062822us-gaap:RetainedEarningsMember2025-12-310001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001062822us-gaap:TreasuryStockCommonMember2025-12-310001062822us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-3100010628222026-01-012026-03-310001062822us-gaap:PreferredStockMemberus-gaap:PreferredStockMember2026-01-012026-03-310001062822us-gaap:AdditionalPaidInCapitalMemberus-gaap:PreferredStockMember2026-01-012026-03-310001062822us-gaap:PreferredStockMember2026-01-012026-03-310001062822us-gaap:CommonStockMemberus-gaap:CommonStockMember2026-01-012026-03-310001062822us-gaap:AdditionalPaidInCapitalMemberus-gaap:CommonStockMember2026-01-012026-03-310001062822us-gaap:CommonStockMember2026-01-012026-03-310001062822us-gaap:AdditionalPaidInCapitalMemberus-gaap:TreasuryStockCommonMember2026-01-012026-03-310001062822us-gaap:TreasuryStockCommonMemberus-gaap:TreasuryStockCommonMember2026-01-012026-03-310001062822us-gaap:TreasuryStockCommonMember2026-01-012026-03-310001062822us-gaap:TreasuryStockCommonMember2026-01-012026-03-310001062822us-gaap:RetainedEarningsMember2026-01-012026-03-310001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001062822us-gaap:CommonStockMember2026-03-310001062822us-gaap:PreferredStockMember2026-03-310001062822us-gaap:AdditionalPaidInCapitalMember2026-03-310001062822us-gaap:RetainedEarningsMember2026-03-310001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001062822us-gaap:TreasuryStockCommonMember2026-03-3100010628222026-03-310001062822us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-300001062822us-gaap:AdditionalPaidInCapitalMemberus-gaap:CommonStockMember2026-04-012026-06-300001062822us-gaap:CommonStockMember2026-04-012026-06-300001062822us-gaap:PreferredStockMember2026-04-012026-06-300001062822us-gaap:RetainedEarningsMember2026-04-012026-06-300001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-012026-06-300001062822us-gaap:CommonStockMember2026-06-300001062822us-gaap:PreferredStockMember2026-06-300001062822us-gaap:AdditionalPaidInCapitalMember2026-06-300001062822us-gaap:RetainedEarningsMember2026-06-300001062822us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-300001062822us-gaap:TreasuryStockCommonMember2026-06-300001062822us-gaap:CashMember2026-06-300001062822us-gaap:USTreasurySecuritiesMember2026-06-300001062822us-gaap:CorporateDebtSecuritiesMember2026-06-300001062822us-gaap:ShortTermInvestmentsMember2026-06-300001062822us-gaap:InvestmentsMember2026-06-300001062822us-gaap:CashMember2025-12-310001062822lxrx:RestrictedCashMember2025-12-310001062822lxrx:CashAndRestrictedCashMember2025-12-310001062822us-gaap:USTreasurySecuritiesMember2025-12-310001062822us-gaap:CorporateDebtSecuritiesMember2025-12-310001062822us-gaap:ShortTermInvestmentsMember2025-12-310001062822us-gaap:InvestmentsMember2025-12-310001062822us-gaap:FairValueInputsLevel1Member2026-06-300001062822us-gaap:FairValueInputsLevel2Member2026-06-300001062822us-gaap:FairValueInputsLevel3Member2026-06-300001062822us-gaap:FairValueInputsLevel1Member2025-12-310001062822us-gaap:FairValueInputsLevel2Member2025-12-310001062822us-gaap:FairValueInputsLevel3Member2025-12-310001062822us-gaap:ComputerEquipmentMembersrt:MinimumMember2026-06-300001062822us-gaap:ComputerEquipmentMembersrt:MaximumMember2026-06-300001062822us-gaap:ComputerEquipmentMember2026-06-300001062822us-gaap:ComputerEquipmentMember2025-12-310001062822us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2026-06-300001062822us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2026-06-300001062822us-gaap:FurnitureAndFixturesMember2026-06-300001062822us-gaap:FurnitureAndFixturesMember2025-12-310001062822us-gaap:LeaseholdsAndLeaseholdImprovementsMembersrt:MinimumMember2026-06-300001062822us-gaap:LeaseholdsAndLeaseholdImprovementsMembersrt:MaximumMember2026-06-300001062822us-gaap:LeaseholdsAndLeaseholdImprovementsMember2026-06-300001062822us-gaap:LeaseholdsAndLeaseholdImprovementsMember2025-12-310001062822lxrx:NovoNordiskMemberus-gaap:LicenseMember2025-04-012025-04-300001062822us-gaap:LicenseMemberlxrx:FirstAndSecondNovoNordiskDevelopmentMilestonesMemberlxrx:NovoNordiskMember2026-01-012026-03-310001062822lxrx:NovoNordiskMemberus-gaap:LicenseMember2026-06-300001062822lxrx:ViatrisInc.Memberus-gaap:LicenseMember2024-10-012024-10-310001062822lxrx:ViatrisInc.Memberus-gaap:LicenseMember2026-06-300001062822us-gaap:LineOfCreditMemberlxrx:HerculesCapitalInc.LoanFacilityMemberus-gaap:SecuredDebtMember2026-05-310001062822us-gaap:LineOfCreditMemberlxrx:HerculesCapitalInc.LoanFacilityMemberus-gaap:SecuredDebtMemberlxrx:DebtTrancheOneMember2026-05-310001062822us-gaap:LineOfCreditMemberlxrx:HerculesCapitalInc.LoanFacilityMemberus-gaap:SecuredDebtMemberlxrx:DebtTrancheTwoMember2026-06-300001062822us-gaap:LineOfCreditMemberlxrx:HerculesCapitalInc.LoanFacilityMemberus-gaap:SecuredDebtMemberlxrx:DebtTrancheThreeMember2026-06-300001062822us-gaap:LineOfCreditMemberlxrx:HerculesCapitalInc.LoanFacilityMemberus-gaap:SecuredDebtMember2026-01-012026-06-300001062822lxrx:DebtTrancheOneMember2026-05-310001062822lxrx:DebtTrancheTwoMember2026-06-300001062822lxrx:DebtTrancheThreeMember2026-06-300001062822us-gaap:LineOfCreditMemberlxrx:HerculesCapitalInc.LoanFacilityMemberus-gaap:SecuredDebtMember2026-06-300001062822us-gaap:LineOfCreditMemberlxrx:HerculesCapitalInc.LoanFacilityMembersrt:ScenarioForecastMemberus-gaap:SecuredDebtMember2027-01-012027-12-310001062822us-gaap:LineOfCreditMemberlxrx:HerculesCapitalInc.LoanFacilityMembersrt:ScenarioForecastMemberus-gaap:SecuredDebtMember2028-01-012028-12-310001062822us-gaap:LineOfCreditMemberlxrx:HerculesCapitalInc.LoanFacilityMembersrt:ScenarioForecastMemberus-gaap:SecuredDebtMember2029-01-012029-12-310001062822us-gaap:LineOfCreditMemberlxrx:HerculesCapitalInc.LoanFacilityMembersrt:ScenarioForecastMemberus-gaap:SecuredDebtMember2030-01-012030-12-310001062822us-gaap:LineOfCreditMemberlxrx:OxfordFinanceLLCTermLoansMemberus-gaap:SecuredDebtMember2026-05-012026-05-310001062822us-gaap:LineOfCreditMemberlxrx:OxfordFinanceLLCTermLoansMemberus-gaap:SecuredDebtMember2025-04-012025-04-300001062822us-gaap:LineOfCreditMemberlxrx:OxfordFinanceLLCTermLoansMemberus-gaap:SecuredDebtMember2025-12-012025-12-310001062822us-gaap:LineOfCreditMemberlxrx:OxfordFinanceLLCTermLoansMemberus-gaap:SecuredDebtMember2026-02-012026-02-280001062822us-gaap:LineOfCreditMemberlxrx:OxfordFinanceLLCTermLoansMemberus-gaap:SecuredDebtMember2026-05-310001062822us-gaap:EmployeeStockOptionMemberlxrx:EmployeesMember2026-01-012026-06-300001062822us-gaap:EmployeeStockOptionMemberlxrx:OfficersAndNonEmployeeDirectorsMember2026-01-012026-06-300001062822us-gaap:EmployeeStockOptionMemberlxrx:EmployeesMember2025-01-012025-06-300001062822us-gaap:EmployeeStockOptionMemberlxrx:OfficersAndNonEmployeeDirectorsMember2025-01-012025-06-300001062822us-gaap:EmployeeStockOptionMember2025-12-310001062822us-gaap:EmployeeStockOptionMember2026-01-012026-06-300001062822us-gaap:EmployeeStockOptionMember2026-06-300001062822us-gaap:RestrictedStockUnitsRSUMember2025-12-310001062822us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-06-300001062822us-gaap:RestrictedStockUnitsRSUMember2026-06-300001062822us-gaap:TreasuryStockCommonMemberus-gaap:TreasuryStockCommonMember2026-01-012026-06-300001062822us-gaap:CommonStockMemberlxrx:PublicOfferingMember2026-02-012026-02-280001062822us-gaap:CommonStockMemberlxrx:PublicOfferingMember2026-02-280001062822us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2026-02-012026-02-280001062822us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2026-02-280001062822us-gaap:SeriesBPreferredStockMemberus-gaap:PrivatePlacementMember2026-02-012026-02-280001062822us-gaap:SeriesBPreferredStockMemberus-gaap:PrivatePlacementMember2026-02-280001062822us-gaap:PrivatePlacementMember2026-02-012026-02-2800010628222026-04-3000010628222026-04-012026-04-300001062822us-gaap:ProductMemberlxrx:ReportableSegmentMember2026-04-012026-06-300001062822us-gaap:ProductMemberlxrx:ReportableSegmentMember2025-04-012025-06-300001062822us-gaap:ProductMemberlxrx:ReportableSegmentMember2026-01-012026-06-300001062822us-gaap:ProductMemberlxrx:ReportableSegmentMember2025-01-012025-06-300001062822us-gaap:LicenseMemberlxrx:ReportableSegmentMember2026-04-012026-06-300001062822us-gaap:LicenseMemberlxrx:ReportableSegmentMember2025-04-012025-06-300001062822us-gaap:LicenseMemberlxrx:ReportableSegmentMember2026-01-012026-06-300001062822us-gaap:LicenseMemberlxrx:ReportableSegmentMember2025-01-012025-06-300001062822lxrx:ReportableSegmentMember2026-04-012026-06-300001062822lxrx:ReportableSegmentMember2025-04-012025-06-300001062822lxrx:ReportableSegmentMember2026-01-012026-06-300001062822lxrx:ReportableSegmentMember2025-01-012025-06-300001062822us-gaap:ResearchAndDevelopmentExpense2026-04-012026-06-300001062822us-gaap:ResearchAndDevelopmentExpense2026-01-012026-06-300001062822us-gaap:GeneralAndAdministrativeExpense2026-04-012026-06-300001062822us-gaap:GeneralAndAdministrativeExpense2026-01-012026-06-300001062822us-gaap:ResearchAndDevelopmentExpense2025-04-012025-06-300001062822us-gaap:ResearchAndDevelopmentExpense2025-01-012025-06-300001062822us-gaap:SellingAndMarketingExpense2025-04-012025-06-300001062822us-gaap:SellingAndMarketingExpense2025-01-012025-06-300001062822us-gaap:GeneralAndAdministrativeExpense2025-04-012025-06-300001062822us-gaap:GeneralAndAdministrativeExpense2025-01-012025-06-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
 (Mark One)
☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended June 30, 2026 
or

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Transition Period from _____________ to _____________
Commission File Number:  000-30111
Lexicon Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware76-0474169
(State or Other Jurisdiction of
Incorporation or Organization)(I.R.S. Employer
Identification Number)

2445 Technology Forest Blvd.
11th Floor
The Woodlands, Texas 77381
(Address of Principal Executive Offices and Zip Code)
(281) 863-3000
(Registrant’s Telephone Number, Including Area Code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001LXRXThe Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.     
 
Yes☑No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)
 
Yes☑No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer              Accelerated filer         Non-accelerated filer   ☑       
Smaller reporting company    ☑       Emerging growth company         
If an emerging growth company, indicate by check mark if the registration has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
 
Yes☐No☑

As of August 3, 2026, 444,955,934 shares of the registrant’s common stock, par value $0.001 per share, were outstanding. 

Lexicon Pharmaceuticals, Inc.
 
Table of Contents
 
Page
Factors Affecting Forward-Looking Statements
2

Part I – Financial Information
3

Item 1.Financial Statements
3

Condensed Consolidated Balance Sheets - June 30, 2026 (unaudited) and December 31, 2025
3

Condensed Consolidated Statements of Comprehensive (Loss) Income (unaudited) - Three and Six Months Ended June 30, 2026 and 2025
4

Condensed Consolidated Statements of Stockholders’ Equity (unaudited) - Three and Six Months Ended June 30, 2026 and 2025
5

Condensed Consolidated Statements of Cash Flows (unaudited) - Six Months Ended June 30, 2026 and 2025
7

Notes to Condensed Consolidated Financial Statements (unaudited)8

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations
17

Item 3.Quantitative and Qualitative Disclosures About Market Risk
23

Item 4.Controls and Procedures
23

Part II – Other Information
24

Item 1.Legal Proceedings
24

Item 1A.Risk Factors
24

Item 5. Other Information
26

Item 6.Exhibits
27

Signatures
28

The Lexicon name and logo, INPEFA® and ZYNQUISTA® are registered trademarks of Lexicon Pharmaceuticals, Inc.

——————

Factors Affecting Forward Looking Statements
This quarterly report on Form 10-Q contains forward-looking statements. These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology including “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “should” or “will” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under “Part II, Item 1A. - Risk Factors” and in our annual report on Form 10-K for the year ended December 31, 2025, that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, future results, levels of activity, performance or achievements may vary materially from our expectations. We are not undertaking any duty to update any of the forward-looking statements after the date of this quarterly report on Form 10-Q to conform these statements to actual results, unless required by law.

2

Part I – Financial Information
 

Item 1.  Financial Statements 

Lexicon Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets
(In thousands, except par value and share amounts)
 
As of June 30,As of December 31,
20262025
Assets(unaudited)
Current assets:
Cash and cash equivalents$40,924 $34,326 
Short-term investments149,686 61,904 
Accounts receivable, net1,643 2,384 
Inventory1,196 281 
Prepaid expenses and other current assets3,128 3,000 
Total current assets196,577 101,895 
Property and equipment, net1,651 1,863 
Goodwill44,543 44,543 
Operating lease right-of-use-assets6,921 7,318 
Restricted cash— 29,000 
Other assets368 368 
Total assets$250,060 $184,987 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$2,343 $3,083 
Accrued liabilities12,363 13,189 

Current portion of long-term debt— 4,595 
Total current liabilities14,706 20,867 
Long-term debt, net 51,437 49,408 
Other long-term liabilities9,392 7,174 
Total liabilities75,535 77,449 
Commitments and contingencies (Note 7)
Stockholders’ Equity:

Convertible preferred stock, $0.01 par value; 5,000,000 shares authorized
2,712,582 and 2,304,147 shares issued at June 30, 2026 and December 31, 2025, respectively; none outstanding at June 30, 2026 and December 31, 2025
— — 
Common stock, $0.001 par value; 900,000,000 shares authorized at June 30, 2026; 446,870,629 and 365,848,216 shares issued, respectively
447 366 
Additional paid-in capital2,227,526 2,129,912 
Accumulated deficit(2,050,401)(2,017,583)
Accumulated other comprehensive (loss) income(204)30 
Treasury stock, at cost, 1,933,747 and 2,381,939 shares, respectively
(2,843)(5,187)
Total stockholders’ equity174,525 107,538 
Total liabilities and stockholders’ equity$250,060 $184,987 

The accompanying notes are an integral part of these condensed consolidated financial statements. 
3

Lexicon Pharmaceuticals, Inc.

Condensed Consolidated Statements of Comprehensive (Loss) Income
(In thousands, except per share amounts)
(Unaudited)

 
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenues:
Net product revenue$680 $1,322 $1,770 $2,584 
Licensing and milestone revenue— 27,544 20,000 27,544 
Royalties and other revenue12 — 24 — 
Total revenues692 28,866 21,794 30,128 
Operating expenses:
Cost of sales39 33 147 63 
Research and development, including stock-based compensation of $1,384, $1,620, $2,753, and $3,194 respectively
17,443 15,747 30,199 31,050 
Selling, general and administrative, including stock-based compensation of $1,952, $1,575, $3,661, and $3,044 respectively
9,750 9,350 18,984 20,958 
Total operating expenses27,232 25,130 49,330 52,071 
(Loss) income from operations(26,540)3,736 (27,536)(21,943)
Interest and other expense (2,609)(2,318)(4,199)(4,153)
Interest and other income1,723 1,834 3,266 4,053 
Loss on early extinguishment of debt(4,349)— (4,349)— 
Net (loss) income$(31,775)$3,252 $(32,818)$(22,043)
Net (loss) income per common share, basic$(0.07)$0.01 $(0.08)$(0.06)
Net (loss) income per common share, diluted$(0.07)$0.01 $(0.08)$(0.06)

Weighted average common shares outstanding, basic437,653 363,294 419,050 362,687 
Weighted average common shares outstanding, diluted437,653 363,570 419,050 362,687 

Other comprehensive (loss) income:
Unrealized loss on investments(74)(39)(234)(133)
Comprehensive (loss) income$(31,849)$3,213 $(33,052)$(22,176)

The accompanying notes are an integral part of these condensed consolidated financial statements.

4

Lexicon Pharmaceuticals, Inc.

Condensed Consolidated Statements of Stockholders’ Equity 
(In thousands) 
(Unaudited)

Common StockPreferred StockAdditionalAccumulated Other
SharesPar ValueSharesPar ValuePaid-In CapitalAccumulated DeficitComprehensive Income (Loss)Treasury StockTotal
Balance at December 31, 2024363,020 $363 — $— $2,117,325 $(1,967,242)$119 $(4,615)$145,950 
Stock-based compensation expense— — — — 3,043 — — — 3,043 

Issuance of common stock under Equity Incentive Plans2,540 3 — — (3)— — — — 
Payments for tax withholding on share-based compensation vesting— — — — — — — (572)(572)
Net loss— — — — — (25,295)— — (25,295)
Unrealized loss on investments— — — — — — (94)— (94)
Balance at March 31, 2025365,560 $366 — $— $2,120,365 $(1,992,537)$25 $(5,187)$123,032 
Stock-based compensation expense— — — — 3,195 — — — 3,195 

Issuance of common stock under Equity Incentive Plans221 — — — — — — — — 

Net income— — — — — 3,252 — — 3,252 
Unrealized loss on investments— — — — — — (39)— (39)
Balance at June 30, 2025365,781 $366 — $— $2,123,560 $(1,989,285)$(14)$(5,187)$129,440 

The accompanying notes are an integral part of these condensed consolidated financial statements.
5

Lexicon Pharmaceuticals, Inc.

Condensed Consolidated Statements of Stockholders’ Equity 
(In thousands) 
(Unaudited)
Common StockPreferred StockAdditionalAccumulated Other
SharesPar ValueSharesPar ValuePaid-In CapitalAccumulated DeficitComprehensive Income (Loss)Treasury StockTotal
Balance at December 31, 2025365,848 $366 — $— $2,129,912 $(2,017,583)$30 $(5,187)$107,538 
Stock-based compensation expense— — — — 3,078 — — — 3,078 
Issuance of preferred stock, net of fees— — 408 4 26,544 — — — 26,548 
Issuance of common stock, net of fees56,489 57 — — 69,616 — — — 69,673 
Issuance of common stock under Equity Incentive Plans3,371 3 — — 62 — — — 65 
Issuance of treasury stock under Equity Incentive Plans— — — — (5,187)— — 5,187 — 
Payments for tax withholding on share-based compensation vesting— — — — — — — (2,843)(2,843)
Net loss— — — — — (1,043)— — (1,043)
Unrealized loss on investments— — — — — — (160)— (160)
Balance at March 31, 2026425,708 $426 408 $4 $2,224,025 $(2,018,626)$(130)$(2,843)$202,856 
Stock-based compensation expense— — — — 3,336 — — — 3,336 

Fees related to issuance of common stock— — — — (50)— — — (50)
Issuance of common stock under Equity Incentive Plans741 1 — — 231 — — — 232 

Conversion of preferred stock to common stock20,422 20 (408)(4)(16)— 
Net loss— — — — — (31,775)— — (31,775)
Unrealized loss on investments— — — — — — (74)— (74)
Balance at June 30, 2026446,871 $447 — $— $2,227,526 $(2,050,401)$(204)$(2,843)$174,525 

The accompanying notes are an integral part of these condensed consolidated financial statements.
6

Lexicon Pharmaceuticals, Inc.
 
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
 
Six Months Ended June 30,
20262025
Cash flows from operating activities:
Net loss$(32,818)$(22,043)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization212 352 
Stock-based compensation6,414 6,238 
Amortization of debt-related costs1,213 803 
Loss on early extinguishment of debt4,349 — 
Accretion of marketable securities purchased at a discount(1,292)(2,540)
Other non-cash adjustments(99)(1,561)
Changes in operating assets and liabilities:
Decrease in accounts receivable, net741 1,290 
(Increase) decrease in inventories(915)63 
(Increase) decrease in prepaid expenses and other current assets(128)806 
Decrease in other long-term assets397 376 
Decrease in accounts payable and other liabilities(1,996)(10,569)
Net cash used in operating activities(23,922)(26,785)
Cash flows from investing activities:

Purchases of investments(163,221)(90,943)
Maturities of investments76,497 147,008 
Net cash (used in) provided by investing activities(86,724)56,065 
Cash flows from financing activities:

Proceeds from issuance of common stock, net of fees70,777 — 
Proceeds from issuance of preferred stock, net of fees26,548 — 
Proceeds from issuance of common stock for equity incentive plans297 — 
Payments for tax withholding on share-based compensation vesting(2,843)(572)
Proceeds from debt borrowings55,000 — 
Repayment of debt borrowings(59,261)(45,000)
Payment of financing fees(2,274)— 
Net cash provided by (used in) financing activities88,244 (45,572)
Net decrease in cash, cash equivalents and restricted cash(22,402)(16,292)
Cash, cash equivalents, and restricted cash at beginning of period63,326 66,656 
Cash, cash equivalents, and restricted cash at end of period$40,924 $50,364 

Supplemental disclosure of cash flow information:
Cash paid for interest$2,606 $4,888 

The accompanying notes are an integral part of these condensed consolidated financial statements.

7

Lexicon Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements
(Unaudited)

1.           Summary of Significant Accounting Policies
 
Basis of Presentation. The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation. These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six month period ended June 30, 2026 are not necessarily indicative of the results that may be expected for the year ended December 31, 2026. For further information, refer to the financial statements and footnotes thereto included in Lexicon’s annual report on Form 10-K for the year ended December 31, 2025, as filed with the SEC. 

Use of Estimates. The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
 
Significant Accounting Policies. There have been no significant changes to our summary of significant policies discussed in our annual report on Form 10-K for the year ended December 31, 2025.

Recent Accounting Pronouncements Issued But Not Yet Adopted. In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disclosures (Subtopic 220-40) – Disaggregation of Income Statement Expenses, which is effective prospectively for annual periods beginning after December 15, 2026, and for interim periods beginning after December 15, 2027. The Company is evaluating the impact of adopting ASU 2024-03. 

8

2.           Cash and Cash Equivalents, Restricted Cash and Investments

The fair value of cash and cash equivalents, restricted cash and investments held are as follows:  
As of June 30, 2026
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
(in thousands)
Cash and cash equivalents$40,925 $— $(1)$40,924 

Securities maturing within one year:
U.S. treasury securities116,967 — (142)116,825 
Corporate debt securities32,922 — (61)32,861 
Total short-term investments$149,889 $— $(203)$149,686 
Total cash and cash equivalents and short-term investments$190,814 $— $(204)$190,610 

As of December 31, 2025
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
(in thousands)
Cash and cash equivalents$34,326 $— $— $34,326 
Restricted cash29,000 — — 29,000 
Total cash and cash equivalents and restricted cash$63,326 $— $— $63,326 
Securities maturing within one year:
U.S. treasury securities39,004 22 — 39,026 
Corporate debt securities22,871 8 (1)22,878 
Total short-term investments$61,875 $30 $(1)$61,904 
Total cash and cash equivalents, restricted cash and short-term investments$125,201 $30 $(1)$125,230 

As of June 30, 2026 and December 31, 2025, Lexicon’s investments in an unrealized loss position had an estimated fair value of $153.7 million and $2.5 million, respectively. During the six month period ended June 30, 2026, there were less than $0.1 million in realized gains and no realized losses. There were no realized gains or losses during the six month period ended June 30, 2025.
 

3.            Fair Value Measurements
 
The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:

•Level 1 - quoted prices in active markets for identical assets, which include U.S. treasury securities 
•Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities
•Level 3 - significant unobservable inputs 
9

The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities. The following tables provide the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above. There were no transfers between Level 1 and Level 2 during the periods presented.

Assets at Fair Value as of June 30, 2026
Level 1Level 2Level 3Total
(in thousands)

Cash and cash equivalents$40,924 $— $— $40,924 
Short-term investments116,825 32,861 — 149,686 

Total cash and cash equivalents and short-term investments $157,749 $32,861 $— $190,610 

Assets at Fair Value as of December 31, 2025
Level 1Level 2Level 3Total
(in thousands)

Cash and cash equivalents$34,326 $— $— $34,326 
Short-term investments39,026 22,878 — 61,904 
Restricted cash29,000 — — $29,000 
Total cash and cash equivalents, short-term investments and restricted cash$102,352 $22,878 $— $125,230 

The carrying amount of prepaid expenses and other assets, accounts payable, and accrued expenses are generally considered to be representative of their respective fair values because of the short-term nature of those instruments. The fair value of the Hercules Term Loan is determined under Level 2 in the fair value hierarchy and approximates carrying value as the loan bears interest at a rate that approximates prevailing market rates for instruments with similar characteristics. See Note 6, Debt Obligations for a further discussion of our debt and related instruments.

4. Supplemental Financial Information

Property and Equipment. 

Estimated Useful LivesAs of June 30,As of December 31,
In Years20262025
(in thousands)

Computers and software3-5
$2,003 $2,003 
Furniture and fixtures5-7
389 389 
Leasehold improvements3-7
2,178 2,178 
Total property and equipment4,570 4,570 
Less: Accumulated depreciation and amortization(2,919)(2,707)
Net property and equipment$1,651 $1,863 

10

Accrued Liabilities.

As of June 30,As of December 31,
20262025
(in thousands)

Accrued research and development services$4,149 $2,932 
Accrued compensation and benefits3,896 6,415 
Short-term lease liability1,642 1,642 
Other2,676 2,200 
Total accrued liabilities$12,363 $13,189 

Net Income (Loss) Per Share. Net income (loss) per common share is computed using the weighted average number of shares of common stock outstanding. Potentially dilutive shares associated with warrants, stock options and restricted stock units totaling 10.6 million and 9.8 million for the three and six months ended June 30, 2026, and totaling 0.1 million for the six months ended June 30, 2025, and our convertible preferred shares further described in Note 9 were not included in the computation of diluted earnings per share because they are antidilutive due to the Company’s net loss in the periods presented. 

5.     Collaborations and Strategic Alliances

Novo Nordisk. In March 2025, the Company entered into an exclusive license agreement with Novo Nordisk A/S (“Novo Nordisk”) for the worldwide development, manufacturing and commercialization of LX9851, the Company’s preclinical drug candidate for obesity and associated cardiometabolic disorders. Under the agreement, the Company received an upfront payment of $45 million in April 2025, achieved the first two development milestones totaling $20 million in the first quarter of 2026 and is eligible to receive (a) up to an aggregate of $465 million upon the achievement of additional specified regulatory and commercial launch milestones and (b) up to an aggregate of $475 million upon the achievement of specified sales milestones. The Company is also entitled to tiered, escalating royalties ranging from single-digit to low-double-digit percentages of annual net sales of LX9851, subject to customary royalty reduction provisions.
Viatris. In October 2024, the Company entered into an exclusive license agreement with Viatris Inc. (“Viatris”) for the development and commercialization of sotagliflozin in all markets outside of the United States and Europe (the “Licensed Territory”) pursuant to which the Company received an upfront payment of $25 million. Lexicon also entered into a manufacturing and supply agreement with Viatris pursuant to which Lexicon supplies the development and commercial requirements of sotagliflozin of Viatris, and Viatris pays an agreed upon transfer price for such supply. Lexicon is also eligible to receive (a) up to an aggregate of $12 million upon the achievement of specified regulatory milestones, (b) up to an aggregate of $185 million upon the achievement of specified sales milestones and (c) tiered royalties ranging from low double-digit to upper-teens percentages of annual net sales of sotagliflozin in the Licensed Territory.

For additional information, please refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

6.          Debt Obligations
Hercules Term Loan. In May 2026, the Company and its subsidiaries entered into a loan and security agreement with Hercules Capital, Inc. and certain of its affiliates (“Hercules”) that provides up to $100 million in borrowing capacity (the “Hercules Term Loan”) available in three tranches, each maturing in May 2030. The first $55 million tranche was funded at closing. The second $20 million tranche is available for draw at the Company’s option by no later than June 15, 2028, subject to the achievement of specified performance milestones and certain additional timing restrictions. The third $25 million tranche is available for draw at the Company’s option, subject to Hercules’s consent, at any time prior to the expiration of the interest-only payment period. 

A final payment (equal to 6.25% of the amount funded under the Hercules Term Loan), is due upon prepayment or maturity of the loan. Additionally, the Company may prepay the Hercules Term Loan in whole or in part at its option at any time. Any prepayment of the Hercules Term Loan is subject to prepayment fees initially equal to 3.0% of the outstanding principal being repaid, subject to a declining scale depending on when prepayment occurs relative to the applicable closing date.

11

Warrants. In connection with the loan and security agreement, the Company agreed to grant Hercules warrants to purchase a number of shares of its common stock equal to 2% of the aggregate principal amount of the Hercules Term Loan made and funded under the loan and security agreement at an exercise price of $1.59 per share. Concurrent with the funding of the first tranche, the Company granted Hercules warrants to purchase 691,823 shares of its common stock. Upon funding of the second and third tranches, the Company will grant Hercules warrants to purchase an additional 251,572 and 314,465 shares of its common stock, respectively. The warrants are exercisable for a five-year period from the date of issuance. 

The Company used the Black-Scholes model to calculate the fair value of the warrants which are reflected in other long-term liabilities on the consolidated balance sheet and reduced the initial carrying value of long-term debt. The fair value was recorded using assumptions of stock price volatility, the expected life of the warrants and the fair value of the common stock underlying the warrants, among other assumptions and will be remeasured each reporting period with changes in fair value recorded in the condensed consolidated statement of comprehensive loss within interest and other expense.

Interest, Principal Payments, and Carrying Value of Debt. Monthly interest-only payments are due during an initial 18-month period, which may be extended to 24 months or 30 months if specified performance milestones are achieved. The interest-only period will be followed by an amortization period extending through the maturity date. The Hercules Term Loan bears interest at a floating rate equal to the prime rate plus 3.10%, but not less than 9.85%. For the quarter ended June 30, 2026, the interest rate of the Hercules Term Loan was 9.85%.

Payments of $3.5 million, $21.3 million, $21.3 million and $12.3 million, including debt principal and the final payment noted above, will be during the fiscal years ended December 31, 2027, December 31, 2028, December 31, 2029 and December 31, 2030, respectively. 

As of June 30, 2026, the carrying value of the Hercules Term Loan in long-term debt on the condensed consolidated balance sheet was $51.4 million primarily reflecting the unamortized balance of debt issuance costs and discounts totaling $3.7 million, which are being amortized into interest and other expense over the life of the loan. 
Restrictive Provisions/Covenants. The Company’s obligations under the Hercules Term Loan are secured by a first lien security interest in all of the assets of the Company and its subsidiaries. Financial covenants include (a) a minimum cash covenant beginning on June 1, 2027, which will be extended to January 1, 2028 upon achievement of specified performance milestones and waived at any time the Company meets specified market capitalization requirements and (b) a minimum revenue covenant relating to net sales of its products beginning only at specified times after the Company draws the second or third tranche, which will be waived at any time the Company meets specified minimum cash and/or market capitalization requirements. The Company was in compliance with its debt covenants as of June 30, 2026.
Oxford Term Loans. Concurrent with its execution of the loan and security agreement with Hercules in May 2026, the Company repaid the remaining $54.3 million (including pro-rata final payment exit fees equal to 7% of the amount funded) under the Oxford Term Loans. In April 2025, December 2025 and February 2026, the Company repaid $45 million, $3 million and $5 million to Oxford, respectively, including pro-rata final payment exit fees equal to 7% of the amount funded under the Oxford Term Loans. In connection with the repayment of the Oxford term loans in May 2026, the Company recorded a loss on early extinguishment of debt of $4.3 million and is no longer subject to the $29 million minimum restricted cash requirement.

For additional information on the Company’s long-term debt obligations, refer to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

7.            Commitments and Contingencies
 
Operating Lease Obligations.  Operating lease right-of-use assets and associated lease liabilities are recorded in the condensed consolidated balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of lease payments. Lexicon does not apply this accounting to those leases with terms of twelve months or less. 

Lexicon’s operating leases include leases of office space in The Woodlands, Texas and Bridgewater, New Jersey that will expire in January 2031 and January 2034, respectively. As of June 30, 2026 and December 31, 2025, the right-of-use assets for the office space leases of $6.9 million and $7.3 million, respectively, are separately included in operating lease right-of-use-assets in the condensed consolidated balance sheet. Current liabilities relating to the leases are included in accrued liabilities in the condensed consolidated balance sheet (as further described in Note 4) and long-term operating lease liabilities of 
12

$6.2 million and $6.6 million, respectively, as of June 30, 2026 and December 31, 2025 are included in other long-term liabilities in the condensed consolidated balance sheet. 

During the three months ended June 30, 2026 and 2025, the Company incurred lease expense of $0.5 million and $0.4 million, respectively. During the six months ended June 30, 2026 and 2025, the Company incurred lease expense of $1.0 million and $0.8 million, respectively. During the six months ended June 30, 2026 and 2025, the Company made cash payments for lease liabilities of $0.9 million and $0.7 million, respectively. As of June 30, 2026 and December 31, 2025, the weighted-average remaining lease terms were 6.5 years and 7.0 years, respectively, with weighted-average discount rates of 10.5% for each year.

13

The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at June 30, 2026:

(in thousands)
2026$795 
20271,683 
20281,718 
20291,753 
20301,863 
Thereafter2,979 
Total undiscounted operating lease liability10,791 
Less: amount of lease payments representing interest(2,987)
Present value of future lease payments7,804 
Less: short-term operating lease liability(1,642)
Long-term operating lease liability$6,162 

Legal Proceedings.  Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.

8.     Equity Incentive Awards

Stock-Based Compensation.  The Company has stockholder-approved equity incentive plans that permit the grant of stock options, restricted stock units, and other stock-based awards to employees, directors, and consultants of the Company. Compensation expense related to stock options and restricted stock units (“RSUs”) is determined based on the fair value of the award on the date of the grant and is recognized on a straight-line basis over the vesting period in which an employee is required to provide service. Compensation expense for the three months ended June 30, 2026 and 2025 of $3.3 million and $3.2 million, respectively, and for the six months ended June 30, 2026 and 2025 of $6.4 million and $6.2 million, respectively, is recorded separately in research and development expense and selling, general, and administrative expense as noted on the Company’s condensed consolidated statements of comprehensive loss.   
 
The fair value of stock options is estimated at the date of grant using the Black-Scholes method requiring the input of subjective assumptions. Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives.  Historical data is used to estimate the expected option life for each group. Expected volatility is based on the historical volatility in the Company’s stock price. The following weighted-average assumptions were used for stock options granted in the six months ended June 30, 2026 and 2025:
Expected VolatilityRisk-free Interest RateExpected TermDividend
Rate
Six Months Ended June 30, 2026
Employees106 %4.0 %4— %
Officers and non-employee directors104 %3.8 %6— %
Six Months Ended June 30, 2025
Employees105 %3.9 %4— %
Officers and non-employee directors115 %4.3 %6— %

14

The following is a summary of stock option activity under Lexicon’s stock-based compensation plans:

Stock OptionsWeighted Average Exercise Price
(in thousands)
Outstanding at December 31, 202520,738 $1.96 
Granted5,455 1.41 
Exercised(209)1.41 
Expired(198)8.66 
Forfeited(305)1.63 
Outstanding at June 30, 202625,481 1.80 
Exercisable at June 30, 202611,379 $2.59 

The following is a summary of restricted stock unit activity under Lexicon’s stock-based compensation plans:
RSU’sWeighted Average Grant Date
Fair Value
(in thousands)
Outstanding at December 31, 202515,469 $0.96 
Granted6,738 1.38 
Vested(6,284)1.10 
Forfeited(418)0.89 
Outstanding at June 30, 202615,505 $1.09 

During the six months ended June 30, 2026, the Company issued treasury shares totaling $5.2 million in lieu of issuing additional authorized common shares in order to satisfy the annual vesting of restricted stock units for its employees and officers. 

9.     Other Capital Agreements
 
2026 Common and Series B Preferred Stock Issuance. In February 2026, Lexicon sold 34,089,403 shares of its common stock in an underwritten public offering for $1.30 per share resulting in net proceeds of approximately $40.6 million (after deducting underwriting discounts and commissions and other offering expenses).

Concurrent with the underwritten public offering, Lexicon sold to certain affiliates of Invus, L.P. in a concurrent private placement (a) 22,400,000 shares of its common stock for $1.30 per share and (b) 408,434.70 shares of its Series B Convertible Preferred Stock for $65.00 per share, which were convertible into 20,421,735 shares of common stock, resulting in aggregate gross proceeds of approximately $55.6 million. 

 In April 2026, following the approval by the Company’s shareholders of the Seventh Amended and Restated Certificate of Incorporation which increased the total authorized shares of common stock from 450,000,000 to 900,000,000 and the filing and acceptance of the Seventh Amended and Restated Certificate of Incorporation by the Secretary of State of Delaware, each share of preferred stock was converted into 50 shares of common stock at par value, or 20,421,735 shares in the aggregate. 

15

10. Segment Information

Lexicon operates as a single reportable segment, primarily focusing on the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Substantially all of the Company’s revenues have been derived from drug discovery alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, technology licenses, subscriptions to its databases, product sales, government grants and contracts and compound library sales, as well as from commercial sales of its approved drug product. 

The chief operating decision maker (“CODM”) is the Company’s chief executive officer (“CEO”). The CEO manages and allocates resources on a total company basis by assessing the overall level of resources available and how to best deploy these resources across research and development projects in line with the Company’s long-term company-wide strategic goals.

The CEO evaluates single-segment consolidated financial information against budget for purposes of making operating decisions, planning and forecasting for future periods, and deciding the level of investment in the Company’s various operating activities and other capital allocation activities. The CODM assesses finan